Clinical Trials Browser

Approved for marketing × Thoracic × Clear all

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Approved for marketing

Thoracic

EGFRm Advanced Non-Small Cell Lung Cancer

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Approved for marketing

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing

Thoracic

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

NCT04535557 2022-09-30

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Approved for marketing

Thoracic

Lung Neoplasms

NCT04204928 2021-08-13

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Approved for marketing

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04291937 2020-06-19

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Approved for marketing

Thoracic

Small Cell Lung Carcinoma

NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Approved for marketing

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01931306 2018-11-14

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01649284 2016-11-30

Afatinib Expanded Access Program

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01209650 2016-11-10

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Approved for marketing

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Approved for marketing

Other solid neoplasmThoracic

Mesothelioma

Clinical Trials

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Early Access Program of Lazertinib in Republic of Korea

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Afatinib Expanded Access Program

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.